28A-1110824
US provisional
Hexanucleotide expansion in C9ORF72 is the most prevalent mutation among patients of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD). There are dipeptide repeats (DPRs) translated from the expansion. Among DPRs, poly-glycine-arginine (GR) and poly-proline-arginine (PR) are the most toxic. We identified a sulfated disaccharide and several heparan sulfates including heparan sulfate disaccharides, tetra-saccharides, and octa-saccharides to bind poly-GR/PR and neutralize poly-GR/PR-induced toxicity in neuroblastoma and C9-iPSC-derived motor neurons. The compound extended the lifespan, rescued the locomotion of poly-GR/PR expressing drosophila, and improved the motor behavior of a poly-GR-injected mouse model. Overall, our results demonstrated that heparan sulfate derivatives have diagnostic and therapeutic potential for Arginine-rich dipeptides in C9-relative neurodegenerative diseases
- There is currently a lack of effective drugs for ALS and FTLD, and the effect of delaying their deterioration is also limited. C9orf72 mutation accounts for the majority among these diseases, so our research has the potential market.
- Drugs for neurodegenerative diseases have to face the obstacle of the blood-brain barrier (BBB). Some literatures show that heparan sulfate oligosaccharide can pass through the BBB.
- The synthesis of heparin sulfate is difficult. The complete molecular library of disaccharides, tetrasaccharides, and octasaccharides is unique in the world. Therefore, we can develop and improve drugs independently and quickly in the future.
- The heparan sulfate derivatives as therapeutics for C9orf72-relative neurodegenerative diseases.
- The heparan sulfate derivatives as prevention for C9orf72-relative neurodegenerative diseases.
- The heparan sulfate derivatives as diagnostic agent for C9orf72-relative neurodegenerative diseases.
Yun-Ru Chen, Shang-Cheng Hung
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Heparan sulfate derivatives for diagnosis and therapy in neurodegenerative diseases